that four 10-minute episodes of ischemia caused virtually no myocyte necrosis (in contrast to an uninterrupted 40-minute episode of ischemia, which typically resulted in a solid subendocardial infarct). Other studies of repeated brief ischemic episodes also revealed minimal structural damage or necrosis10-12 and little cumulative effect on tissue adenine nucleotide content.91113-15 It is also noteworthy that postischemic contractile function deteriorates only slightly from one occlusion to another, with a cumulative effect becoming detectable only with multiple occlusions. 16-'8 The metabolic consequences of repeated ischemic episodes observed experimentally are particularly intriguing: In our studies,9 a single 10-minute episode of ischemia caused loss of 60% of ATP, and only half of the lost ATP was resynthesized during a 20-minute period of reperfusion (because adenine nucleotides had been lost and are only slowly synthesized in myocardium). Nevertheless, the second, third, and fourth 10-minute episodes of ischemia caused no cumulative ATP depletion. ATP and adenine nudleotide contents of myocardium after four 10-minute ischemic episodes were similar to those after only one. Moreover, although substantial quantities of adenine nucleosides and bases (products of adenine nucleotide degradation) were produced in the first ischemic episode, much less was produced in later episodes. These results were the first indication that the rate of energy metabolism of ischemic myocardium was different if the myocardium had already been recently exposed to ischemia.
The most striking observation, however, was that myocardial infarct size produced by a 40-minute test period of coronary occlusion was reduced by 75% (from 29% to 7% of the ischemic vascular bed at risk) when the myocardium had first been subjected to four 5-minute episodes of coronary occlusion, each separated by 5 minutes of reperfusion.19 This dramatically increased tolerance of cardiac myocytes to an ordinarily lethal ischemic insult, achieved by an initial brief exposure to ischemia, was termed "ischemic preconditioning." Whether ischemic preconditioning results in increased tolerance to ischemia in humans has heretofore been unknown. However, the paper by Deutsch et al in this issue of Circulation20 presents clinical, ECG, and coronary flow data from 12 patients, as well as lactate extraction data from another seven, who were undergoing elective coronary angioplasty. The effects of two sequential 90-second occlusions of the anterior descending artery, separated by 5 minutes of reperfusion, were compared. The second episode of ischemia caused less chest pain and less ST segment elevation in all 19 patients, and less myocardial lactate production in the group of seven patients, than did the first episode. These changes were associated with reduced cardiac vein flow from the ischemic region, suggesting that the apparently lesser severity of ischemia was not due to increased collateral flow but indeed reflected an adaptation to myocardial ischemia. Although these data are necessarily indirect, they provide strong evidence that the phenomenon of ischemic preconditioning observed in animal models also occurs in humans with atherosclerotic heart disease.
The phenomenon of ischemic preconditioning has been confirmed to exist in dogs by other investigators21 and has been reported to occur in pigs22 and rabbits23 as well. In dogs, the protective effect has been achieved by one or more ischemic episodes ranging from 5 to 15 minutes in duration. 19, 21 The increased tolerance to ischemia results in a prolongation of the reversible phase of injury of myocytes and has also been reported to preserve efferent sympathetic and vagal responses in a subsequent ischemic episode.24 However, the following limitations have been observed: 1) The protective effect was lost in experimental studies when the test episode of injury was extended to 3 hours,20 and 2) much of the protective effect was lost if the reperfusion time between the initial preconditioning episode(s) of ischemia and the later test episode was extended to 2 hours. 25 Repeated brief episodes of ischemia have also been reported to affect myocardial arrhythmogenesis. For example, a 5-minute episode of myocardial ischemia in rats reduced the incidence of ischemia and/or reperfusion arrhythmias caused by a subsequent 5-minute episode of ischemia.26 This antiarrhythmic effect has also been termed "ischemic preconditioning." However, in our canine studies one or two 10-minute episodes of ischemia were, paradoxically, associated with an increased incidence of ventricular fibrillation during a later 10-or 40-minute episode of ischemia and/or reperfusion9J9 (also K.A. Reimer, C.E. Murry, and R.B. Jennings, unpublished observations, 1986). Thus, it is not known whether the antiarrhythmic effects of ischemic preconditioning in rats are a manifestation of the increased myocyte tolerance to ischemia that defines ischemic preconditioning in larger animal species.
The cellular protection afforded by preconditioning is associated with a marked slowing of ischemic metabolism during the test episode.27 This slowing of metabolism involves both the production and utilization of high energy phosphates. In severe ischemia, anaerobic glycolysis is the principal source of new ATP production28; in preconditioned ischemic myocardium, the entire glycolytic pathway is slowed. This is reflected by markedly less accumulation in the tissue not only of lactate but also of proximal glycolytic intermediates, including glucose-i-phosphate and glucose-6-phosphate. 27 The slowed rate of glycolysis occurs despite an increased glucose content in the tissue at the onset of the test period of ischemia.27 Glycogenolysis is correspondingly slowed, although substantial quantities of glycogen are still present in the myocytes at the onset of the test episode of ischemia.
Experimental studies have begun to shed some light on the mechanism of preconditioning, but much remains to be learned. Understanding the mechanism of reduced ATP consumption in preconditioned myocardium requires elucidation of those reactions that account for the utilization of ATP in ischemic myocardium. In aerobic myocardium, mechanical function accounts for the majority of the ATP utilized. The reactions that consume most of the ATP during ischemia are poorly defined, but some ATP surely is expended in feeble attempts of the ischemic myocytes to contract. We postulated25 that if this accounts for a major fraction of ATP utilization in ischemia, preconditioning might simply be a manifestation of stunning; that is, preischemic dysfunction might be translated into a reduced contractile effort and therefore a reduced demand for ATP during the test episode of ischemia. Along similar lines, it has been reported that a brief episode of ischemia resulted in a more rapid onset of contractile failure during a subsequent episode.17 Confuting our hypothesis is the observation that four 5-minute episodes of coronary occlusion, which was the first preconditioning protocol by which dramatic protection was achieved, cause relatively mild stunning (C.E. Murry, R.B. Jennings, K.A. Reimer, unpublished observation, 1988). Moreover, in a direct study of the link between stunning and preconditioning,25 we observed that a single 15-minute episode of ischemia caused severe stunning that persisted throughout 2 hours of reperfusion. Marked limitation of infarct size was observed when the test episode of ischemia followed the preconditioning episode after 5 minutes of reperfusion. However, much of the protection was lost when the test occlusion was delayed for 2 hours. Thus, although it is possible that stunning contributes to the reduced metabolic rate of preconditioned myocardium, stunning alone is insufficient to cause preconditioning.
Recent studies have indicated that a major cause of ATP degradation in ischemia is the squandering of ATP by the mitochondrial ATPase29,30 and that in "slow heart rate" species, including rabbits and larger mammals, the rate of ATP degradation is modulated by a natural protein inhibitor of the ATPase that binds to the enzyme during mitochondrial acidosis induced by ischemia. 31 The possibility that such inhibition might occur more quickly or more completely during a second episode of ischemia and thereby explain preconditioning is an intriguing hypothesis, but one for which no data yet exists.
Another hypothesis is that the cardiac adaptation to ischemia results from a rapid expression of gene products analogous to the induction of stress proteins after heat shock. Indeed, synthesis of mRNA for stress proteins has been detected in myocardium within 2 hours after a 15-minute episode of ischemia.32 However, a genetic mechanism must be consistent with the biology of the preconditioning phenomenon: preconditioning is achieved within a 5-minute reperfusion period and is mostly lost after 2 hours of reperfusion. Thus, whether any such gene expression will prove to be activated and deactivated sufficiently quickly to explain the induction and loss of preconditioning is presently unknown.
It also remains to be established whether the phenomenon of ischemic preconditioning can be exploited therapeutically. For example, it seems likely that the duration of balloon inflation during coronary angioplasty might be safely increased if the procedure is preceded by an initial shorter coronary occlusion. Whether ischemic preconditioning might increase the cardiac tolerance to ischemic cardiac arrest during cardiac surgery and thereby serve as an adjunct to other means of cardioplegia is unknown, but the possibility is surely worth investigating in experimental models. Whether it will become possible to induce ischemic tolerance in patients with angina pectoris is also unknown; answering this question will most likely depend on elucidation of the underlying cellular mechanism of ischemic preconditioning.
